Tekmira’s $1bn RNAi suit costs Alnylam $65m as firms kiss and make up
This article was originally published in Scrip
Executive Summary
Alnylam and Tekmira have ended their ongoing row over Tekmira's RNA interface technologies. The two firms have settled all litigation and restructured their relationship with a new licensing agreement, which Alnylam says gives it independence in lipid nanoparticle (LNP) manufacturing.